- Previous Close
49.86 - Open
50.06 - Bid 51.69 x 200
- Ask 51.87 x 100
- Day's Range
49.85 - 51.86 - 52 Week Range
19.81 - 61.61 - Volume
257,050 - Avg. Volume
553,642 - Market Cap (intraday)
3.532B - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-2.89 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
89.00
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
www.merus.nlRecent News: MRUS
View More
Performance Overview: MRUS
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRUS
View MoreValuation Measures
Market Cap
3.53B
Enterprise Value
2.75B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
85.13
Price/Book (mrq)
4.72
Enterprise Value/Revenue
78.18
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.62%
Return on Equity (ttm)
-33.39%
Revenue (ttm)
35.19M
Net Income Avi to Common (ttm)
-167.66M
Diluted EPS (ttm)
-2.89
Balance Sheet and Cash Flow
Total Cash (mrq)
787.42M
Total Debt/Equity (mrq)
1.48%
Levered Free Cash Flow (ttm)
-77.82M
Research Analysis: MRUS
View MoreCompany Insights: MRUS
MRUS does not have Company Insights
Research Reports: MRUS
View MoreDaily – Vickers Top Buyers & Sellers for 10/12/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/11/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/02/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/25/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.